Form 4: Bio-Rad Laboratories EVP Colleen Corey Reports Stock Transactions
SEC Form 4
Colleen Corey, EVP of Global Human Resources at Bio-Rad Laboratories, reported multiple transactions involving Bio-Rad A Common Stock, including acquisitions from restricted stock unit vesting and disposals to cover tax obligations.
Summary
- Colleen Corey, EVP of Global Human Resources at Bio-Rad Laboratories, filed a Form 4 detailing changes in beneficial ownership of Bio-Rad A Common Stock.
- The reported transactions occurred between September 1, 2024, and September 3, 2024.
- Corey acquired shares through the vesting of restricted stock units (RSUs).
- She also disposed of shares to satisfy tax withholding obligations related to the vesting of these RSUs.
- The price for disposals to cover tax obligations was $337.32 on September 1st and 2nd, and $334.31 on September 3rd.
- The transactions resulted in a net increase in Corey's direct holdings of Bio-Rad A Common Stock, from 17,723 to 18,479 shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The document simply reports stock transactions by an executive, which is a normal part of corporate activity. There is no indication of positive or negative sentiment towards the company's prospects.
Positives
- The vesting of restricted stock units suggests that Corey is meeting performance milestones or tenure requirements.
- Increased ownership aligns Corey's interests with those of other shareholders.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Monitoring insider transactions is a common practice in the financial industry.
- Comparing Corey's transactions to those of other executives at Bio-Rad and peer companies (e.g., Danaher, Thermo Fisher Scientific) could provide context on the scale and frequency of her stock activity.
- Analyzing the vesting schedules of RSUs relative to industry norms can also offer insights into Bio-Rad's compensation practices.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders.
- Shareholders may view insider transactions as a signal of management's confidence (or lack thereof) in the company, but these transactions appear routine.
Key Dates
| Date | Description |
|---|---|
| 09/03/2019 | Reporting person was granted 2,475 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. |
| 09/02/2020 | Reporting person was granted 1,444 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. |
| 09/01/2021 | Reporting person was granted 1,013 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. |
| 09/01/2022 | Reporting person was granted 1,388 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. |
| 09/01/2023 | Reporting person was granted 2,003 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. |
| 09/01/2024 | Transaction Date: Shares of Class A common stock acquired on the vesting of restricted stock units. |
| 09/02/2024 | Transaction Date: Shares of Class A common stock acquired on the vesting of restricted stock units. |
| 09/03/2024 | Transaction Date: Shares of Class A common stock acquired on the vesting of restricted stock units. |
| 09/04/2024 | Date of report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.